Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

• Lobeglitazone is a novel PPAR-γ agonist containing the TZD motif.
• Lobeglitazone is mainly excreted in feces, thereby reducing the risk of bladder cancer.
• Lobeglitazone showed a favorable balance of efficacy and safety in patients with type 2 diabetes during 52 weeks.

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.